NIBAN1

Across TCGA pan-cancer cohorts, NIBAN1 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of NIBAN1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where NIBAN1 RNA is repressed in tumor relative to normal tissue. In most cancer types NIBAN1 is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and KIRC are the cancer types where NIBAN1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NIBAN1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	−2.872	<.001	11	view →
COAD	Male	II,III,IV	−2.416	<.001	11	view →
KIRC	Male	All	+1.190	<.001	11	view →
LUAD	All	II,III,IV	−0.683	.001	7	view →
UCEC	All	All	−2.189	<.001	6	view →
BRCA	All	III,IV	−1.299	<.001	6	view →
LIHC	All	All	+0.754	<.001	6	view →
STAD	Female	All	−2.397	<.001	4	view →
PAAD	All	All	−0.604	.021	4	view →
LUSC	Male	All	−0.594	.002	4	view →
READ	All	All	−3.363	<.001	3	view →
KIRP	All	All	+0.943	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

NIBAN1–BLCA

Open the BLCA breakdown →